More Startups
This investment carries considerable risks and may lead to a loss of the entire assets invested. Projected returns cannot be guaranteed and may be lower than expected.

Beloren | Overview

Beloren is the first privately funded prescription medication on Companisto.
Pitch Video

Degode recreated the patented prescription medication Beloren for the treatment of acne and rosacea (generic medication). The development is so accurate that 5 EU regulatory authorities have already confirmed that we are eligible for approval without the need for costly studies. EU sales are already secured: The sales partner Aristo guarantees minimum purchase quantities in the first 5 years and thus a total turnover of at least EUR 2.5 million.

Degode Key Investment Facts Beloren


The pharmaceutical company Degode is the first German generics manufacturer to run an equity crowdfunding campaign and is thus breaking new ground.

The product Beloren is a reimbursable prescription medication for acne and rosacea. Degode is the first manufacturer to offer this medication as a generic medication (copy of a medication with the same active ingredient) of the original medication patented in the EU until the end of 2018.

The original product Skinoren generates an annual worldwide turnover of approximately EUR 150 million in over 70 countries. The worldwide market for acne medication is forecast to grow by 75% (currently: USD 3.1 billion worldwide).

Degodehas already succeeded in concluding a sales contract with the major German pharmacy coorporation Aristo.  

The sales contract guarantees Degode a fixed minimum purchase quantity for the 11 EU countries with the hihgest sales in the first 5 years after market launch. This results in a total sales volume of at least EUR 2.5 million.

Degode also receives an advance payment from Aristo for the exclusive distribution rights as well as the option to sell these distribution rights for the 11 countries after 5 years. Moreover, license negotiations are currently underway for the United States & Brazil.

Typically, the approval process for generics is very complex because development takes several years and costs tens of millions of euros.

Furthermore, the chance of approval by the BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte - Federal Institute for Drugs and Medical Devices) for the first time is very low.

Degode has succeeded in developing a formula so close to the original product that the EU authorities waived the customary long-term studies that would cost EUR 14 million.


Degode - Approval Process in 3 Phases Beloren


A final test in the form of a larger validation batch (largest possible batch comparable to the later commercial size) is now pending as the last step.

Since the production is determined by the quantities purchased and the required batch sizes, Degode is able to produce much more cost-effectively than the original.

The large generics manufacturers avoid risk in this market and concentrate mainly on medications with turnovers of at least EUR 500 million (blockbusters).

Degode - Top 3 Generika Producer


Degode was founded by Sven Schimansky-Wabra. With more than 8 years of experience in the pharmaceutical industry, he has already successfully developed and received approval for 5 formulas of a generic medication for skin care.

He receives the support of several experts from the pharmaceutical industry, such as Prof. Markus Veit, Prof. Martin Sieber, and Dr. Francisco Harrison, who serve on the advisory board.

With the help of the Companists, Degode wants to take the last step towards the approval of the medication and be the first generics manufacturer to serve a lucrative market and to look forward to high and secure sales over the next 5 years.

Please note
The acquisition of the offered securities and investments is associated with considerable risks and can lead to the complete loss of the invested assets. The expected yield is not guaranteed and may be lower. Whether it is a security or an asset investment can be seen in the description of the investment opportunity.
Contact Us
If you have any questions about investing on Companisto, please contact our service team:

Toll-free phone number for investors calling from Germany:
0800 - 100 267 0

Companisto investors hotline:
+49(0)30 - 346 491 493

We are available Monday through Friday between 9 a.m. – 6 p.m.

For companies
Apply for financing Investment Model FAQ for Companies
Investor Support
Please register in order to see the complete profile of Beloren.
Already registered?    Log in